Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 22 von 24 | SupStack

Metformin – Forschungsarchiv

Studien 2001–2050 von 2110, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

2001RCT2000

Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M · J Clin Endocrinol Metab (2000)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

Metformin and contrast media--a dangerous combination?

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Efficacy of metformin in the treatment of NIDDM. Meta-analysis.

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.

Repaglinide in combination therapy with metformin in Type 2 diabetes.

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.

Relating in vitro/in vivo data of two controlled-release metformin formulations.

[Metformin in the UKPDS study. Metabolic and vascular results].

Effect of metformin on patients with impaired glucose tolerance.

Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity.

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance.

Metformin added to insulin therapy in poorly controlled type 2 diabetes.

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.

Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients.

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.

Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus.

[Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].

Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.

Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease.

Effect of metformin on food intake in obese subjects.

The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients.

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

Metformin and exercise: no additive effect on blood lactate levels in health volunteers.

Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.

Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients.

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.

Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.